Login / Signup
Marc Pfeffer presented the results of PARADISE-MI at ACC last week. As discussed previously on CVCTCardiobrief, sacubitril/valsartan did not reduce the primary outcome compared to…
High Rate of Crossovers in ADAPTABLE Aspirin Dosing Trial
Until now the optimal dosing of aspirin in terms of efficacy and safety for secondary prevention of atherosclerotic cardiovascular disease had not been previously well…